ADMA Biologics Inc (ADMA) exhibits 57.4% gross margins and 32.9% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 12.4x enterprise multiple and 4.8% implied options volatility.
Sustained 57.4% gross profitability converts into 37.5% operating margin and 32.9% ROIC, outpacing sector cost of capital.
ROIC: 32.9% // GM: 57.4%YoY revenue trajectory of +19.6% paired with 1.06% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +19.6% // FCF YLD: 1.06%Altman Z-Score of 12.98 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 12.98 // F-SCORE: 7/9Trading at 17.9x trailing P/E (15.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 17.9x // EV/EBITDA: 12.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $11.75 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 28.8% net margins.
NET MARGIN: 28.8% // D/E: 0.15x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ADMA & activate live FRED threshold breach alerts.